September 17, 2016 08:07 AM EDT
R&D

No­var­tis shows a hole card in a high-stakes PhI­II pok­er game for MS drugs

John Carroll

Editor & Founder

No­var­tis float­ed a new, pos­i­tive da­ta point from its re­cent­ly com­plet­ed Phase III study of sipon­i­mod (BAF312), an S1P re­cep­tor drug that is be­ing ad­vanced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times